Loading…
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $24M | $-450M | $-243M | $-370M | -80.8% | - | -17.3% |
| 2024 | $0M | $-298M | $-294M | $-257M | -113.1% | - | 89.8% |
| 2023 | $0M | $-157M | $-155M | $-134M | 45.7% | - | 38.5% |
| 2022 | $0M | $-114M | $-112M | $-110M | 57.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 24.05 |
| Operating Revenue | 0 | 0 | 0 | 24.05 |
| Operating Expense | 113.85 | 158.17 | 300.75 | 477.85 |
| Research And Development | 101.30 | 137.68 | 265.55 | 386 |
| Selling General And Administration | 12.55 | 20.50 | 35.20 | 91.86 |
| Total Expenses | 113.85 | 158.17 | 300.75 | 477.85 |
| Operating Income | -113.85 | -158.17 | -300.75 | -453.80 |
| Total Operating Income As Reported | -113.85 | -158.17 | -300.75 | -453.80 |
| EBITDA | -113.60 | -156.89 | -297.60 | -450.31 |
| Normalized EBITDA | -113.60 | -156.77 | -292.20 | -638.22 |
| EBIT | -113.85 | -158.17 | -300.75 | -453.80 |
| Interest Income | 1.99 | 3.37 | 12.02 | 14.18 |
| Net Interest Income | 1.99 | 3.37 | 12.02 | 14.18 |
| Other Non Operating Income Expenses | -0.07 | -0.07 | -0.09 | -0.17 |
| Other Income Expense | -0.07 | -0.19 | -5.50 | 187.74 |
| Interest Income Non Operating | 1.99 | 3.37 | 12.02 | 14.18 |
| Net Non Operating Interest Income Expense | 1.99 | 3.37 | 12.02 | 14.18 |
| Pretax Income | -111.93 | -154.99 | -294.23 | -251.89 |
| Tax Provision | - | - | 0 | -8.56 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 6.39 |
| Net Income Continuous Operations | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income From Continuing And Discontinued Operation | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income From Continuing Operation Net Minority Interest | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income Common Stockholders | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income Including Noncontrolling Interests | -111.93 | -154.99 | -294.23 | -243.32 |
| Normalized Income | -111.93 | -154.87 | -288.83 | -424.84 |
| Diluted NI Availto Com Stockholders | -111.93 | -154.99 | -294.23 | -243.32 |
| Basic Average Shares | 38.41 | 51.84 | 28.34 | - |
| Diluted Average Shares | 38.41 | 51.84 | 28.34 | - |
| Reconciled Depreciation | 0.25 | 1.28 | 3.15 | 3.50 |
| Total Unusual Items | - | -0.12 | -5.41 | 187.91 |
| Total Unusual Items Excluding Goodwill | - | -0.12 | -5.41 | 187.91 |
| Special Income Charges | - | - | 0 | 187.91 |
| Restructuring And Mergern Acquisition | - | - | 0 | -187.91 |
| Gain On Sale Of Security | - | -0.12 | -5.41 | - |
| General And Administrative Expense | 12.55 | 20.50 | 35.20 | 91.86 |
| Other Gand A | 12.55 | 20.50 | 35.20 | 91.86 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Alumis Inc.this co. | ALMS | $2.6B | -10.68 | 8.63 | -80.8% | -5.66 |
| Soleno Therapeutics, Inc. | SLNO | $2.8B | 132.26 | 6.14 | 4.6% | 96.72 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.7B | -170.10 | 14.49 | -8.5% | 1582.53 |
| Disc Medicine, Inc. | IRON | $2.7B | -12.80 | 3.67 | -28.7% | -12.77 |
| Definium Therapeutics, Inc. | DFTX | $2.7B | -14.59 |
| 8.07 |
| -55.3% |
| -13.82 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B | -39.09 | 7.56 | -19.3% | -45.85 |
| Guardian Pharmacy Services, Inc. | GRDN | $2.6B | 52.49 | 12.56 | 23.9% | 26.50 |
| IDEAYA Biosciences, Inc. | IDYA | $2.6B | -22.58 | 2.51 | -11.1% | -16.04 |
| Heartflow, Inc. | HTFL | $2.5B | -21.27 | 8.26 | -38.8% | -26.44 |
| Peer Median | - | -17.93 | 7.81 | -15.2% | -13.30 | |